Published in Am J Cardiol on August 15, 2005
Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab (2009) 3.98
Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol (2014) 3.45
Knowledge and attitudes of primary care physicians in the management of patients at risk for cardiovascular events. BMC Fam Pract (2008) 1.32
Clinical efficacy and safety of statins in managing cardiovascular risk. Vasc Health Risk Manag (2008) 1.30
Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response. Circ Cardiovasc Genet (2008) 1.17
Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis. J Am Heart Assoc (2012) 1.11
Prevalence of dyslipidemia in statin-treated patients in Canada: results of the DYSlipidemia International Study (DYSIS). Can J Cardiol (2010) 1.05
Use of Lipid-Lowering Medications and the Likelihood of Achieving Optimal LDL-Cholesterol Goals in Coronary Artery Disease Patients. Cholesterol (2012) 1.03
Prevalence and overlap of different lipid abnormalities in statin-treated patients at high cardiovascular risk in clinical practice in Germany. Clin Res Cardiol (2010) 1.03
Barriers to non-HDL cholesterol goal attainment by providers. Am J Med (2011) 1.01
Lipid-lowering therapy: who can benefit? Vasc Health Risk Manag (2011) 1.01
Effectiveness of combined statin plus omega-3 fatty acid therapy for mixed dyslipidemia. Am J Cardiol (2008) 0.99
Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care (2012) 0.97
Effects of prescription omega-3-acid ethyl esters on non--high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin. Mayo Clin Proc (2010) 0.97
Non-HDL cholesterol as a metric of good quality of care: opportunities and challenges. Tex Heart Inst J (2011) 0.97
Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin. J Lipid Res (2014) 0.94
Modifiable factors associated with failure to attain low-density lipoprotein cholesterol goal at 6 months after acute myocardial infarction. Am Heart J (2012) 0.92
Implications of the obesity epidemic for lipid-lowering therapy: non-HDL cholesterol should replace LDL cholesterol as the primary therapeutic target. Vasc Health Risk Manag (2008) 0.90
Trends in low-density lipoprotein cholesterol goal achievement in high risk United States adults: longitudinal findings from the 1999-2008 National Health and Nutrition Examination Surveys. PLoS One (2013) 0.88
Opening a new lipid "apo-thecary": incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular risk. Mayo Clin Proc (2011) 0.87
Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals. Vasc Health Risk Manag (2009) 0.86
Ethnic differences in achievement of cholesterol treatment goals. Results from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology II. J Gen Intern Med (2006) 0.85
Therapeutic RNA manipulation in liver disease. Hepatology (2010) 0.85
Clinical utility of rosuvastatin and other statins for cardiovascular risk reduction among the elderly. Clin Interv Aging (2010) 0.84
Effect of Ezetimibe on LDL-C Lowering and Atherogenic Lipoprotein Profiles in Type 2 Diabetic Patients Poorly Controlled by Statins. PLoS One (2015) 0.84
Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin. Eur Heart J (2014) 0.84
A comparison of Canadian and American guidelines for lipid management using data from the National Cholesterol Education Program Evaluation ProjecT Utilizing Novel E-technology (NEPTUNE) II survey. Can J Cardiol (2006) 0.82
Understanding hypertriglyceridemia in women: clinical impact and management with prescription omega-3-acid ethyl esters. Int J Womens Health (2011) 0.82
Optimal lipid modification: the rationale for combination therapy. Vasc Health Risk Manag (2005) 0.82
Efficacy and tolerability of adding coenzyme A 400 U/d capsule to stable statin therapy for the treatment of patients with mixed dyslipidemia: an 8-week, multicenter, double-blind, randomized, placebo-controlled study. Lipids Health Dis (2014) 0.82
Pitavastatin: evidence for its place in treatment of hypercholesterolemia. Core Evid (2010) 0.81
First-line treatment patterns and lipid target levels attainment in very high cardiovascular risk outpatients. Lipids Health Dis (2013) 0.81
Differences in cholesterol management among states in relation to health insurance and race/ethnicity across the United States. J Clin Lipidol (2013) 0.81
Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9. J Lipid Res (2015) 0.81
Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglycerides. Cardiovasc Drugs Ther (2011) 0.81
Combination of statin and ezetimibe for the treatment of dyslipidemias and the prevention of coronary artery disease. Can J Cardiol (2006) 0.80
Circulating PCSK9 levels and CETP plasma activity are independently associated in patients with metabolic diseases. Cardiovasc Diabetol (2016) 0.80
Adherence of hospital-based cardiologists to lipid guidelines in patients at high risk for cardiovascular events (2L registry). Clin Res Cardiol (2010) 0.79
The evaluation of low-density lipoprotein cholesterol goals achieved in patients with established cardiovascular disease and/or hyperlipidaemia receiving lipid-lowering therapy: the South African Not at Goal study (SA-NAG). Cardiovasc J Afr (2008) 0.78
Applied pharmacogenomics in cardiovascular medicine. Annu Rev Med (2013) 0.78
Changes in low-density lipoprotein cholesterol levels after discharge for acute myocardial infarction in a real-world patient population. Am J Epidemiol (2014) 0.77
Factors Associated with Lipid Goal Attainment among Patients with Deployed Drug Eluting Stent. Zhonghua Minguo Xin Zang Xue Hui Za Zhi (2014) 0.77
Lowering low-density lipoprotein cholesterol levels in patients with type 2 diabetes mellitus. Int J Gen Med (2014) 0.76
Colesevelam hydrochloride: evidence for its use in the treatment of hypercholesterolemia and type 2 diabetes mellitus with insights into mechanism of action. Core Evid (2012) 0.76
Unmet need in the hyperlipidaemia population with high risk of cardiovascular disease: a targeted literature review of observational studies. BMC Cardiovasc Disord (2016) 0.75
The combination of Ezetimibe and Statin: a new treatment for hypercholesterolemia. Heart Int (2007) 0.75
SLCO1B1 genetic variants, long-term low-density lipoprotein cholesterol levels and clinical events in patients following cardiac catheterization. Pharmacogenomics (2015) 0.75
A Review of Currently Available Fenofibrate and Fenofibric Acid Formulations. Cardiol Res (2013) 0.75
Managing dyslipidemia in primary care with restricted access to lipid-modifying therapy. Am Health Drug Benefits (2010) 0.75
Colesevelam hydrochloride: reducing atherosclerotic coronary heart disease risk factors. Vasc Health Risk Manag (2007) 0.75
Clinical Outcomes according to the Achievement of Target Low Density Lipoprotein-Cholesterol in Patients with Acute Myocardial Infarction. Korean Circ J (2016) 0.75
Effect of physician characteristics and knowledge on the quality of dyslipidemia management and LDL-C target goal achievement in China: Subgroup analysis of the Dyslipidemia International Study. J Glob Health (2017) 0.75
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med (2007) 25.17
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation (2004) 23.07
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25
Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic Impact Goal through 2020 and beyond. Circulation (2010) 13.28
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 11.88
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation (2013) 10.07
Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA (2006) 9.27
Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation (2009) 8.11
AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation (2006) 8.01
Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med (2012) 7.93
Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med (2008) 7.75
Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2010) 6.93
Relationship between early physician follow-up and 30-day readmission among Medicare beneficiaries hospitalized for heart failure. JAMA (2010) 6.91
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol (2004) 6.50
T-cell accumulation and regulated on activation, normal T cell expressed and secreted upregulation in adipose tissue in obesity. Circulation (2007) 6.23
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med (2015) 6.12
Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study. J Am Coll Cardiol (2010) 5.79
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol (2003) 5.77
Comparison of the instructional efficacy of Internet-based CME with live interactive CME workshops: a randomized controlled trial. JAMA (2005) 5.50
Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med (2014) 5.47
Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes (2003) 5.43
Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. JAMA (2013) 5.05
Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail (2013) 4.98
Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure. JAMA (2007) 4.89
Epidemiology and risk profile of heart failure. Nat Rev Cardiol (2010) 4.88
Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation (2011) 4.78
Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet (2010) 4.72
Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet (2011) 4.67
ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol (2002) 4.50
The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care (2005) 4.38
Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA (2006) 4.30
Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol (2005) 4.26
An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch Intern Med (2006) 4.23
A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med (2014) 4.14
Get With the Guidelines-Stroke is associated with sustained improvement in care for patients hospitalized with acute stroke or transient ischemic attack. Circulation (2008) 4.00
Identifying individuals at high risk for diabetes: The Atherosclerosis Risk in Communities study. Diabetes Care (2005) 3.96
High-density lipoprotein as a therapeutic target: a systematic review. JAMA (2007) 3.92
Lipid-related markers and cardiovascular disease prediction. JAMA (2012) 3.91
Chronic hyperglycemia and subclinical myocardial injury. J Am Coll Cardiol (2012) 3.91
2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation (2013) 3.86
Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels. Circulation (2011) 3.68
Linking inpatient clinical registry data to Medicare claims data using indirect identifiers. Am Heart J (2009) 3.57
Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med (2011) 3.52
Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure. Am J Med (2013) 3.46
Fluid retention is associated with cardiovascular mortality in patients undergoing long-term hemodialysis. Circulation (2009) 3.43
Evidence-based guidelines for cardiovascular disease prevention in women. Circulation (2004) 3.39
Intraluminal crawling of neutrophils to emigration sites: a molecularly distinct process from adhesion in the recruitment cascade. J Exp Med (2006) 3.38
Cardiorenal interactions: insights from the ESCAPE trial. J Am Coll Cardiol (2008) 3.35
State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail (2008) 3.35
Correlates of repeat lipid testing in patients with coronary heart disease. JAMA Intern Med (2013) 3.30
ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Circulation (2002) 3.29
Body mass index and mortality in heart failure: a meta-analysis. Am Heart J (2008) 3.25
Rehospitalization for heart failure: problems and perspectives. J Am Coll Cardiol (2012) 3.24
Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21
Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med (2012) 3.15
Sleep apnea is associated with subclinical myocardial injury in the community. The ARIC-SHHS study. Am J Respir Crit Care Med (2013) 3.09
Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol (2004) 3.08
Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator. JAMA (2012) 3.07
Sex-hormone-binding globulin and the free androgen index are related to cardiovascular risk factors in multiethnic premenopausal and perimenopausal women enrolled in the Study of Women Across the Nation (SWAN). Circulation (2005) 3.01
Use of aldosterone antagonists in heart failure. JAMA (2009) 3.00
Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol (2002) 2.97
Is hospital admission for heart failure really necessary?: the role of the emergency department and observation unit in preventing hospitalization and rehospitalization. J Am Coll Cardiol (2013) 2.89
The importance of population-wide sodium reduction as a means to prevent cardiovascular disease and stroke: a call to action from the American Heart Association. Circulation (2011) 2.89
Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention. J Am Coll Cardiol (2010) 2.86
Development and validation of a patient self-assessment score for diabetes risk. Ann Intern Med (2009) 2.85
Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur Heart J (2007) 2.80
High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail (2007) 2.75
The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res (2004) 2.72
In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol (2005) 2.71
Predictors of adherence to performance measures in patients with acute myocardial infarction. Am J Med (2012) 2.64
Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur J Heart Fail (2010) 2.64
Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol (2006) 2.59
AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol (2006) 2.57
Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol (2007) 2.56
Racial and ethnic differences in the treatment of acute myocardial infarction: findings from the Get With the Guidelines-Coronary Artery Disease program. Circulation (2010) 2.53
Adiponectin is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction in patients presenting with chest pain. Eur Heart J (2006) 2.47
An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. J Am Coll Cardiol (2013) 2.47
A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J (2007) 2.44
A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. J Am Coll Cardiol (2005) 2.42
Cardiac troponin and outcome in acute heart failure. N Engl J Med (2008) 2.41
Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). J Am Coll Cardiol (2008) 2.39
Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes (2004) 2.38